CA3145936A1 - Combinaison de vaccins et methode d'utilisation - Google Patents
Combinaison de vaccins et methode d'utilisationInfo
- Publication number
- CA3145936A1 CA3145936A1 CA3145936A CA3145936A CA3145936A1 CA 3145936 A1 CA3145936 A1 CA 3145936A1 CA 3145936 A CA3145936 A CA 3145936A CA 3145936 A CA3145936 A CA 3145936A CA 3145936 A1 CA3145936 A1 CA 3145936A1
- Authority
- CA
- Canada
- Prior art keywords
- hpv
- protein
- vaccine
- seq
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 149
- 238000000034 method Methods 0.000 title claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 145
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 138
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 91
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 91
- 241000341655 Human papillomavirus type 16 Species 0.000 claims abstract description 64
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 28
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 28
- 239000002157 polynucleotide Substances 0.000 claims abstract description 28
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims abstract description 17
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims abstract description 17
- 241000341657 Human papillomavirus type 18 Species 0.000 claims description 59
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 21
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 14
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 14
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 14
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 14
- 150000001413 amino acids Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 9
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 9
- 230000037452 priming Effects 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 7
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 6
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 238000009169 immunotherapy Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 238000002659 cell therapy Methods 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 238000000315 cryotherapy Methods 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- 238000011127 radiochemotherapy Methods 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000002626 targeted therapy Methods 0.000 claims description 4
- 238000000015 thermotherapy Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 3
- 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 claims description 3
- 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 241000701806 Human papillomavirus Species 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 37
- 239000000427 antigen Substances 0.000 description 36
- 102000036639 antigens Human genes 0.000 description 29
- 108091007433 antigens Proteins 0.000 description 29
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 16
- 102000053602 DNA Human genes 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 230000028993 immune response Effects 0.000 description 15
- 239000012634 fragment Substances 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 7
- 108010041986 DNA Vaccines Proteins 0.000 description 7
- 229940021995 DNA vaccine Drugs 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000021633 leukocyte mediated immunity Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 6
- 101000954519 Human papillomavirus type 18 Protein E6 Proteins 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 108090000144 Human Proteins Proteins 0.000 description 5
- 102000003839 Human Proteins Human genes 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 241000700618 Vaccinia virus Species 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102100035857 Glutamate decarboxylase 2 Human genes 0.000 description 2
- 101000767629 Human papillomavirus type 18 Protein E7 Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 108010024780 glutamate decarboxylase 2 Proteins 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- WORLVFQFRWYCAV-CDQZISKASA-N (4s,5r)-4-hydroxy-4-[(e)-5-hydroxy-3-methylpent-3-en-1-ynyl]-3,3,5-trimethylcyclohexan-1-one Chemical compound C[C@@H]1CC(=O)CC(C)(C)[C@]1(O)C#C\C(C)=C\CO WORLVFQFRWYCAV-CDQZISKASA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- 229940124957 Cervarix Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 229940124897 Gardasil Drugs 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 239000004186 Penicillin G benzathine Substances 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000881059 Vaccinia virus Wyeth Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000000787 conjunctival cancer Diseases 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000002023 papillomaviral effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940124954 vaccinia virus vaccine Drugs 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3145936A CA3145936A1 (fr) | 2022-01-18 | 2022-01-18 | Combinaison de vaccins et methode d'utilisation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3145936A CA3145936A1 (fr) | 2022-01-18 | 2022-01-18 | Combinaison de vaccins et methode d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3145936A1 true CA3145936A1 (fr) | 2023-07-18 |
Family
ID=87245311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3145936A Pending CA3145936A1 (fr) | 2022-01-18 | 2022-01-18 | Combinaison de vaccins et methode d'utilisation |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA3145936A1 (fr) |
-
2022
- 2022-01-18 CA CA3145936A patent/CA3145936A1/fr active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018203170B2 (en) | Multimeric Fusion Protein Vaccine And Immunotherapeutic | |
| RU2619187C2 (ru) | Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа | |
| Liu et al. | Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer | |
| Vici et al. | Immunologic treatments for precancerous lesions and uterine cervical cancer | |
| Hung et al. | A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors | |
| Wick et al. | A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors | |
| Sadraeian et al. | Induction of antitumor immunity against cervical cancer by protein HPV-16 E7 in fusion with ricin B chain in tumor-bearing mice | |
| JP2022046617A (ja) | 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用 | |
| CA2985381A1 (fr) | Compositions de vaccin contre le syndrome reproducteur et respiratoire porcin et les maladies associees au circovirus porcin | |
| US7132262B2 (en) | Papilloma virus sequences | |
| Lin et al. | DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity | |
| US20230226164A1 (en) | Vaccine combination and method for using the same | |
| CA3206004A1 (fr) | Constructions virales destinees a etre utilisees dans l'amelioration de l'amorcage de lymphocytes t pendant la vaccination | |
| Garmory et al. | DNA vaccines for biodefence | |
| Porchia et al. | Purified herpes simplex type 1 glycoprotein D (gD) genetically fused with the type 16 human papillomavirus E7 oncoprotein enhances antigen-specific CD8+ T cell responses and confers protective antitumor immunity | |
| Decrausaz et al. | Induction of human papillomavirus oncogene‐specific CD8 T‐cell effector responses in the genital mucosa of vaccinated mice | |
| CA3145936A1 (fr) | Combinaison de vaccins et methode d'utilisation | |
| JP2015524420A (ja) | ＨＰＶ／ＣｙａＡベースのキメラタンパク質並びにＨＰＶ感染及びＨＰＶ誘導性障害に対する免疫応答の誘導におけるその使用 | |
| JP7385684B2 (ja) | ワクチンの組み合わせ及びその使用方法 | |
| AU2022200326A1 (en) | Vaccine combination and method for using the same | |
| Meshkat et al. | Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene | |
| Lin et al. | Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin | |
| AU2021385555B2 (en) | Dna vaccine for human palillomavirus and method for using the same | |
| EP1401493B1 (fr) | Vaccins sous-unites et leurs procedes de production | |
| CN112423783A (zh) | 组合的预防性和治疗性疫苗 |